MedTrace Logo

A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C

NCT01659567 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 516

Last updated 2017-10-03

Study results available
· View outcomes & findings →

Summary

This prospective observational study will investigate predictive values of virological response in pegylated interferon alfa-2a (Pegasys)/ribavirin (Copegus) treatment-naive participants with chronic hepatitis C. Participants will be treated with pegylated interferon alfa-2a and ribavirin as prescribed by the physician. Data will be collected for a maximum of 96 weeks.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Pegylated Interferon Alfa-2a

Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.

DRUG

Ribavirin

Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-06
Primary Completion
2015-10-20
Completion
2015-10-20
FDA Drug
Yes

Countries

  • Georgia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01659567 on ClinicalTrials.gov